CCRN
Cross Country Healthcare, Inc.
Medical - Care Facilities
Market Cap$326M
5Y Perf.+66.6%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
CCRN vs DBVT vs ALKS vs AMN
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1721.78T
5Y Perf.-58.6%
ALKS
Alkermes plc
Biotechnology
Market Cap$5.89B
5Y Perf.+115.9%
AMN
AMN Healthcare Services, Inc.
Medical - Care Facilities
Market Cap$811M
5Y Perf.-52.7%
CCRN vs DBVT vs ALKS vs AMN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CCRN | DBVT | ALKS | AMN |
|---|---|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology | Biotechnology | Medical - Care Facilities |
| Market Cap | $326M | $1721.78T | $5.89B | $811M |
| Revenue (TTM) | $1.05B | $0.00 | $1.56B | $2.73B |
| Net Income (TTM) | $-95M | $-168M | $153M | $-96M |
| Gross Margin | 18.7% | — | 65.4% | 25.7% |
| Operating Margin | -0.3% | — | 12.3% | -3.5% |
| Forward P/E | 103.4x | — | 24.7x | 10.3x |
| Total Debt | $2M | $22M | $70M | $803M |
| Cash & Equiv. | $109M | $194M | $1.12B | $34M |
CCRN vs DBVT vs ALKS vs AMN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CCRN
DBVT
ALKS
AMN
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cross Country Healt… (CCRN) | 100 | 166.6 | +66.6% |
| DBV Technologies S.… (DBVT) | 100 | 41.4 | -58.6% |
| Alkermes plc (ALKS) | 100 | 215.9 | +115.9% |
| AMN Healthcare Serv… (AMN) | 100 | 47.3 | -52.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CCRN vs DBVT vs ALKS vs AMN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ALKS leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Cross Country Healthcare, Inc. is the stronger pick specifically for capital preservation and lower volatility. DBVT and AMN also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
CCRN
Cross Country Healthcare, Inc.
The Income Pick
CCRN is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- Dividend streak 1 yrs, beta 0.78
- Lower volatility, beta 0.78, Low D/E 0.7%, current ratio 3.78x
- Beta 0.78, current ratio 3.78x
- Beta 0.78 vs DBVT's 1.26, lower leverage
Best for: income & stability and sleep-well-at-night
DBVT
DBV Technologies S.A.
The Momentum Pick
DBVT is the clearest fit if your priority is momentum.
- +114.1% vs CCRN's -26.6%
Best for: momentum
ALKS
Alkermes plc
The Growth Play
ALKS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -5.2%, EPS growth -34.1%, 3Y rev CAGR 9.9%
- -7.7% 10Y total return vs CCRN's -28.1%
- -5.2% revenue growth vs DBVT's -100.0%
- 9.8% margin vs CCRN's -9.0%
Best for: growth exposure and long-term compounding
AMN
AMN Healthcare Services, Inc.
The Value Play
AMN is the clearest fit if your priority is value.
- Lower P/E (10.3x vs 24.7x)
Best for: value
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ALKS | -5.2% revenue growth vs DBVT's -100.0% |
| Value | AMN | Lower P/E (10.3x vs 24.7x) |
| Quality / Margins | ALKS | 9.8% margin vs CCRN's -9.0% |
| Stability / Safety | CCRN | Beta 0.78 vs DBVT's 1.26, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | DBVT | +114.1% vs CCRN's -26.6% |
| Efficiency (ROA) | ALKS | 5.4% ROA vs DBVT's -89.0% |
CCRN vs DBVT vs ALKS vs AMN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
FY 2025
FY 2025
CCRN vs DBVT vs ALKS vs AMN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLALKSLAGGINGAMN
Who Leads Where
ALKS leads in 2 of 6 categories
AMN leads 1 • DBVT leads 1 • CCRN leads 1 • 1 tied
Explore the data ↓AMNAMN Healthcare Servic…
1leads
DBVTDBV Technologies S.A.
1leads
CCRNCross Country Healthc…
1leads
ALKSAlkermes plc
2leads
6 Total Categories
CATEGORYLEADERvs CCRNvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ALKS5/6
Valuation MetricsMultiples, price ratios, and targets
AMN5/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ALKS7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
CCRN1/1
Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AMN and DBVT operate at a comparable scale, with $2.7B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to CCRN's -9.0%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CCRNCross Country Hea… | DBVTDBV Technologies … | ALKSAlkermes plc | AMNAMN Healthcare Se… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $1.1B | $0 | $1.6B | $2.7B |
| EBITDAEarnings before interest/tax | $13M | -$112M | $212M | $62M |
| Net IncomeAfter-tax profit | -$95M | -$168M | $153M | -$96M |
| Free Cash FlowCash after capex | $42M | -$151M | $392M | $234M |
| Gross MarginGross profit ÷ Revenue | +18.7% | — | +65.4% | +25.7% |
| Operating MarginEBIT ÷ Revenue | -0.3% | — | +12.3% | -3.5% |
| Net MarginNet income ÷ Revenue | -9.0% | — | +9.8% | -3.5% |
| FCF MarginFCF ÷ Revenue | +4.0% | — | +25.1% | +8.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -23.6% | — | +28.2% | +1.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -20.3% | +91.5% | -4.1% | +95.9% |
ALKS leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
AMN leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, AMN's 8.3x EV/EBITDA is more attractive than ALKS's 17.2x.
| Metric | CCRNCross Country Hea… | DBVTDBV Technologies … | ALKSAlkermes plc | AMNAMN Healthcare Se… |
|---|---|---|---|---|
| Market CapShares × price | $326M | $1721.78T | $5.9B | $811M |
| Enterprise ValueMkt cap + debt − cash | $220M | $1721.78T | $4.8B | $1.6B |
| Trailing P/EPrice ÷ TTM EPS | -3.45x | -0.76x | 24.70x | -8.46x |
| Forward P/EPrice ÷ next-FY EPS est. | 103.37x | — | — | 10.31x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 16.49x | — | 17.20x | 8.33x |
| Price / SalesMarket cap ÷ Revenue | 0.31x | — | 3.99x | 0.30x |
| Price / BookPrice ÷ Book value/share | 1.01x | 0.66x | 3.28x | 1.26x |
| Price / FCFMarket cap ÷ FCF | 6.76x | — | 12.25x | 3.47x |
AMN leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
ALKS leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to AMN's 1.25x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | CCRNCross Country Hea… | DBVTDBV Technologies … | ALKSAlkermes plc | AMNAMN Healthcare Se… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -24.3% | -130.2% | +8.8% | -14.7% |
| ROA (TTM)Return on assets | -17.9% | -89.0% | +5.4% | -4.3% |
| ROICReturn on invested capital | -0.9% | — | +18.9% | +1.6% |
| ROCEReturn on capital employed | -0.8% | -145.7% | +14.2% | +2.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 7 | 5 |
| Debt / EquityFinancial leverage | 0.01x | 0.13x | 0.04x | 1.25x |
| Net DebtTotal debt minus cash | -$106M | -$172M | -$1.0B | $769M |
| Cash & Equiv.Liquid assets | $109M | $194M | $1.1B | $34M |
| Total DebtShort + long-term debt | $2M | $22M | $70M | $803M |
| Interest CoverageEBIT ÷ Interest expense | -1.56x | -189.82x | 32.30x | -1.22x |
ALKS leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,047 today (with dividends reinvested), compared to $2,366 for AMN. Over the past 12 months, DBVT leads with a +114.1% total return vs CCRN's -26.6%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.4% vs AMN's -38.5% — a key indicator of consistent wealth creation.
| Metric | CCRNCross Country Hea… | DBVTDBV Technologies … | ALKSAlkermes plc | AMNAMN Healthcare Se… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +25.4% | +5.5% | +25.0% | +38.7% |
| 1-Year ReturnPast 12 months | -26.6% | +114.1% | +16.3% | +7.1% |
| 3-Year ReturnCumulative with dividends | -57.0% | +20.4% | +14.3% | -76.8% |
| 5-Year ReturnCumulative with dividends | -37.2% | -66.6% | +60.5% | -76.3% |
| 10-Year ReturnCumulative with dividends | -28.1% | -86.8% | -7.7% | -44.1% |
| CAGR (3Y)Annualised 3-year return | -24.5% | +6.4% | +4.5% | -38.5% |
DBVT leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CCRN and ALKS each lead in 1 of 2 comparable metrics.
Risk & Volatility
CCRN is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.5% from its 52-week high vs CCRN's 67.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CCRNCross Country Hea… | DBVTDBV Technologies … | ALKSAlkermes plc | AMNAMN Healthcare Se… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.78x | 1.26x | 1.06x | 1.08x |
| 52-Week HighHighest price in past year | $14.99 | $26.18 | $36.60 | $23.74 |
| 52-Week LowLowest price in past year | $7.43 | $7.53 | $25.17 | $14.87 |
| % of 52W HighCurrent price vs 52-week peak | +67.4% | +76.8% | +96.5% | +88.4% |
| RSI (14)Momentum oscillator 0–100 | 67.4 | 43.8 | 66.6 | 60.3 |
| Avg Volume (50D)Average daily shares traded | 451K | 253K | 2.3M | 839K |
Evenly matched — CCRN and ALKS each lead in 1 of 2 comparable metrics.
Analyst Outlook
CCRN leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: CCRN as "Hold", DBVT as "Buy", ALKS as "Buy", AMN as "Buy". Consensus price targets imply 130.5% upside for DBVT (target: $46) vs 4.9% for CCRN (target: $11).
| Metric | CCRNCross Country Hea… | DBVTDBV Technologies … | ALKSAlkermes plc | AMNAMN Healthcare Se… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $10.61 | $46.33 | $44.00 | $22.50 |
| # AnalystsCovering analysts | 14 | 15 | 28 | 17 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.5% | +0.3% |
CCRN leads this category, winning 1 of 1 comparable metric.
Key Takeaway
ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AMN leads in 1 (Valuation Metrics). 1 tied.
Best OverallAlkermes plc (ALKS)Leads 2 of 6 categories
Loading custom metrics...
CCRN vs DBVT vs ALKS vs AMN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CCRN or DBVT or ALKS or AMN a better buy right now?
For growth investors, Alkermes plc (ALKS) is the stronger pick with -5.
2% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). Alkermes plc (ALKS) offers the better valuation at 24. 7x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CCRN or DBVT or ALKS or AMN?
On forward P/E, AMN Healthcare Services, Inc.
is actually cheaper at 10. 3x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — CCRN or DBVT or ALKS or AMN?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
5%, compared to -76. 3% for AMN Healthcare Services, Inc. (AMN). Over 10 years, the gap is even starker: ALKS returned -7. 7% versus DBVT's -86. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CCRN or DBVT or ALKS or AMN?
By beta (market sensitivity over 5 years), Cross Country Healthcare, Inc.
(CCRN) is the lower-risk stock at 0. 78β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 62% more volatile than CCRN relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 125% for AMN Healthcare Services, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CCRN or DBVT or ALKS or AMN?
By revenue growth (latest reported year), Alkermes plc (ALKS) is pulling ahead at -5.
2% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: AMN Healthcare Services, Inc. grew EPS 35. 6% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CCRN or DBVT or ALKS or AMN?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -0. 3% for CCRN. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CCRN or DBVT or ALKS or AMN more undervalued right now?
On forward earnings alone, AMN Healthcare Services, Inc.
(AMN) trades at 10. 3x forward P/E versus 103. 4x for Cross Country Healthcare, Inc. — 93. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 130. 5% to $46. 33.
08Which pays a better dividend — CCRN or DBVT or ALKS or AMN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is CCRN or DBVT or ALKS or AMN better for a retirement portfolio?
For long-horizon retirement investors, Cross Country Healthcare, Inc.
(CCRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 78)). Both have compounded well over 10 years (CCRN: -28. 1%, DBVT: -86. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CCRN and DBVT and ALKS and AMN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.